A DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ARO-APOC3 IN ADULTS WITH MIXED DYSLIPIDEMIA
- Registry ID
- AROAPOC3-2002
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- ARROWHEAD PHARMACEUTICALS, INC.
- Start date
- 2022-08-18
- Completion date
- 2023-08-14
- Last update
- 2021-09-01
Conditions
Related clinical trials
- A DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, MULTICENTER STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY ON LDL-C OF EVOLOCUMAB (AMG 145) IN SUBJECTS WITH HIV AND WITH HYPERLIPIDEMIA AND/OR MIXED DYSLIPIDEMIN
- A 52 WEEK, PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPDEMIA OR MIXED DYSLIPIDEMIA AT RISK OF CARDIOVASCULAR EVENTS. SPIRE-LL: STUDIES OF PCSK9 INHIBITION AND THE REDUCTION OF VASCULAR EVENTS - LIPID LOWERING
- "A MULTICENTER, CONTROLLED, OPEN-LABEL EXTENSION (OLE) STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF AMG 145."
View on source registry